Medtronic’s VenaSeal Proves Durable In Five-Year Results
Executive Summary
Five-year outcomes from the VeClose Extension Study at the 2019 Charing Cross Symposium in London show the aggregate complete closure rate of the great saphenous vein was 94.6% in chronic venous disease patients treated with VenaSeal.